Published: 22 May 2020
Author(s): Giuseppe Boriani, Jacopo Francesco Imberti, Marco Vitolo
Issue: July 2020
Section: Commentary

The management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndromes (ACS) and/or undergoing percutaneous coronary interventions (PCI) is highly complex. For this reason, during the last decade cardiovascular research has been focused on finding the best balance between ischemic and hemorrhagic risk in such patients.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.